Phergain study

Author: dshv

August undefined, 2024

WebAbstract. Disrupted protein folding or decreased protein stability can lead to the accumulation of (partially) un- or misfolded proteins, which ultimately cause the … WebDec 13, 2024 · “To our knowledge, LINGain is the first study to assess the evolution of peripheral αβ and γδ T cells in the context of neoadjuvant chemotherapy-free regimen with trastuzumab and pertuzumab in HER2 [+] EBC patients.

PHERGain-2: a study of a new therapeutic strategy to avoid

WebOct 28, 2024 · The protocol of the PerELISA study can be found in Supplementary Material. Patients recruited started letrozole 2.5 mg p.o. daily for 2 weeks followed by a core-biopsy for Ki67 evaluation. Webthe phergain study CLINICAL TRIAL DETAILS THE STUDY ASSESS THE EARLY METABOLIC EFFECTS OF NEOADJUVANT TREATMENT WITH TRASTUZUMAB AND PERTUZUMAB (± … intake manifold in french

Chemotherapy de-escalation using an 18 F-FDG-PET-based

WebFeb 15, 2024 · PHERGain-2 study is an additional step forward and aims to assess the feasibility of chemotherapy de-escalation with neoadjuvant HP followed by adjuvant HP or T-DM1 using a pathological response-adapted strategy in low-risk HER2-positive early breast cancer pts. Trial Design: PHERGain-2 is a multicenter, open-label, non-comparative, phase … WebThe PHERGain study: A.3.2: Name or abbreviated title of the trial where available: PHERGain: A.4.1: Sponsor's protocol code number: MedOPP096-MO39229: A.7: ... The end of study will be three years from surgery (for cohorts A and B and for cohort C only if surgery is performed), up to three years from randomization of the last patient (for ... WebJun 10, 2024 · The addition of trastuzumab to chemotherapy dramatically improved the prognosis of early-stage human epidermal growth factor receptor 2 (HER2)–positive breast cancer. However, 15%-31% of patients still develop disease recurrence, on the basis of long-term follow-up of adjuvant pivotal trials. A better understanding of tumor biology has led … intake manifold heater hose fitting

Trastuzumab and pertuzumab without chemotherapy in early …

Françoise Montravers

WebOct 27, 2024 · The PHERGain study is still ongoing and results on long-term survival are expected to be released in 2024. Clinical Trial Registration: NCT03161353 … WebFeb 1, 2024 · Study record managers: refer to the Data Element Definitions if submitting registration or results information. Search for terms ... (PHERGAIN-2) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. intake manifold heat sinkWebJun 19, 2024 · The PHERGAIN study is evaluating the use of positron emission tomography (PET) imaging during neoadjuvant therapy to monitor tumor response in patients with HER2-positive breast cancer. In preliminary results, investigators reported that patients whose PET scan showed positive response to the treatment had pathological complete response. jobs opportunities in zambia 2022

"WebOct 27, 2024 · This is a summary of a publication about the PHERGain study, which was published in The Lancet Oncology in May 2024. The study includes 376 women with a type of breast cancer called HER2-positive ... " - Phergain study

Phergain study

WebApr 10, 2024 · Background: Anticancer treatments are improving the prognosis of patients fighting cancer. However, anticancer treatments may also increase the cardiovascular (CV) risk by increasing metabolic disorders. Atherosclerosis and atherothrombosis related to anticancer treatments may lead to ischemic heart disease (IHD), while direct cardiac … WebFeb 10, 2024 · The PHERGain II study's goal is to find an effective therapeutic strategy that can reduce the use of chemotherapy and improve the quality of life of patients without …

Did you know?

WebFeb 1, 2024 · Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer (PHERGAIN-2) The safety and scientific … WebMay 25, 2024 · PHERGain assessed early metabolic response by F-PET to neoadjuvant HP and the opportunity of CT de-escalation with a response-adapted strategy in patients …

WebMay 18, 2024 · PHERGain was a strategy-based study with a unique design. Previous trials of de-escalation strategies in HER2-positive, early-stage breast cancer have highlighted the importance of establishing innovative clinical designs, together with optimal selection of … WebMay 29, 2024 · PHERGAIN In another trial, researchers showed that early evaluation of metabolic response using 18 F-FDG PET/CT could help identify patients who will develop a pCR to dual HER2 blockade alone, potentially …

WebJan 24, 2024 · In early stage HER2-positive breast cancer, trials exploring different de-escalation strategies were presented; the PHERGAIN study evaluating response-adapted treatment is promising, but data on long-term outcomes are still awaited. WebNational Center for Biotechnology Information

WebJun 29, 2024 · PHERGain met its first co-primary endpoint by showing that 37.9% of patients who received dual HER2 blockade with trastuzumab and pertuzumab, with or without endocrine therapy, and who were [18FDG-PET] responders achieved a pathological complete response in the breast and axilla and, accordingly, might avoid chemotherapy as part of …

WebThe definitive assessment of pathological complete response was done at this primary analysis; follow-up to assess invasive disease-free survival is continuing, hence these … intake manifold honda civicWebFeb 3, 2024 · PHERGain-2: a study of a new therapeutic strategy to avoid chemotherapy in breast cancer patients. Updated: Dec 7, 2024. We have initiated the PHERGain-2 clinical … jobs opportunity in qatar vs dubaiWebJun 3, 2024 · PHERGain study Early results have shown that interim PET seems to be surrogate marker for pCR and the BCS rates are not compromised in the chemo free strategy and also with a favourable toxicity profile. Hence, a PET-adapted approach seems to be a promising modality for escalation, de-escalation strategy. jobs op schipholWebThe PHERGain study, can you speak to that? Erika P. Hamilton (11:47): PHERGain was a very complicated study. Essentially what they did is they used antibody HER2 treatment and dropped the chemotherapy out for some patients, and other patients got chemotherapy with HER2 treatment. jobs orangeburg sc part timeWebJun 14, 2010 · Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study. Ann Oncol. 2024;29(3):646-653. doi:10.1093/annonc/mdx773 PubMedGoogle … intake manifold hose connectorWebJul 12, 2024 · PARP inhibitors (PARPi), olaparib and talazoparib, are indicated in patients with HER2-negative advanced breast cancer with germline BRCA1/2 mutations. Preclinical data have demonstrated an interaction between DNA damage induced by PARPi and the immune system. intake manifold in engineWebMay 19, 2024 · The study assess the early metabolic effects of neoadjuvant treatment with trastuzumab and pertuzumab (± endocrine therapy) on the primary tumor and axillary … intake manifold leak fix